2016
Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control.
Thomas DA, West M, Legler A, Maslin B, Kim RK, Vadivelu N. Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control. Current Drug Safety 2016, 11: 196-205. PMID: 27113953, DOI: 10.2174/1574886311666160426130444.Peer-Reviewed Original ResearchConceptsPain controlNonopioid analgesicsSide effectsContemporary pain managementOptimum pain controlPerioperative pain controlAcute postoperative painPostoperative pain controlMultiple side effectsNonopioid medicationsPostoperative painTolerant patientsPain managementSafety profileAnalgesicsRecent dataComorbiditiesMedicationsOpioidsPainPatientsSurgeryMainstayControl
2015
Tapentadol extended release in the management of peripheral diabetic neuropathic pain
Vadivelu N, Kai A, Maslin B, Kodumudi G, Legler A, Berger JM. Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Therapeutics And Clinical Risk Management 2015, Volume 11: 95-105. PMID: 25609974, PMCID: PMC4298300, DOI: 10.2147/tcrm.s32193.Peer-Reviewed Original ResearchPainful diabetic neuropathyDiabetic neuropathyOpioid-based therapyCancer-related painDiabetic neuropathic painChronic pain conditionsGastrointestinal side effectsNorepinephrine reuptake inhibitorsΜ-opioid agonistMechanism of actionNeuropathic painPain conditionsReuptake inhibitorsBack painArthritic painClinical efficacyEffective medicationsClinical studiesSide effectsPainTapentadolNeuropathyOne-thirdMedicationsDiabetes
2013
Clinical applications of oxymorphone.
Vadivelu N, Maria M, Jolly S, Rosenbloom J, Prasad A, Kaye AD. Clinical applications of oxymorphone. Journal Of Opioid Management 2013, 9: 439-52. PMID: 24481932, DOI: 10.5055/jom.2013.0186.Peer-Reviewed Original ResearchConceptsNew oral preparationNew oral formulationSemisynthetic opioid analgesicSpecific side effectsSevere painOpioid analgesicsParenteral formClinical indicationsOral preparationsStudy populationPharmacological considerationsOral formulationSide effectsPatient needsUS FoodDrug AdministrationHealthcare providersParenteral formulationsClinical applicationPainImportant drugsOxymorphoneAdditional optionPyridomorphinansSpecific considerationsPatient considerations in the use of tapentadol for moderate to severe pain
Vadivelu N, Huang Y, Mirante B, Jacoby M, Braveman FR, Hines RL, Sinatra R. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthcare And Patient Safety 2013, Volume 5: 151-159. PMID: 23861601, PMCID: PMC3704302, DOI: 10.2147/dhps.s28829.Peer-Reviewed Original ResearchTapentadol ERTapentadol IRSevere painChronic painOpioid agonistsClinical trialsSide effectsChronic painful diabetic neuropathyMu-opioid receptor agonistCentral nervous system depressantsSimilar pain reliefTraditional opioid agonistsUncontrolled postoperative painSevere acute painSevere chronic painGastrointestinal adverse effectsPainful diabetic neuropathyCommon side effectsNorepinephrine reuptake inhibitorsPost-surgical patientsOpioid receptor agonistsUse of tapentadolDrug Administration approvalMonoamine oxidase inhibitorsPotent opioid agonist
2008
Management of chronic pain in the elderly: focus on transdermal buprenorphine
Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clinical Interventions In Aging 2008, Volume 3: 421-430. PMID: 18982913, PMCID: PMC2682375, DOI: 10.2147/cia.s1880.Peer-Reviewed Original ResearchConceptsChronic painTransdermal buprenorphineSafety profileChronic cancer painChronic nonmalignant painNew treatment optionsRelative safety profileCancer painNonmalignant painRespiratory depressionRenal failureTreatment optionsAnalgesic agentsCeiling doseAnalgesic propertiesPainSide effectsClinical practiceBuprenorphineOlder individualsCeiling effectsMetabolic changesDose dumpingSafe useRecent scientific studies